207 related articles for article (PubMed ID: 35688908)
1. TACSTD2 upregulation is an early reaction to lung infection.
Lenárt S; Lenárt P; Knopfová L; Kotasová H; Pelková V; Sedláková V; Vacek O; Pokludová J; Čan V; Šmarda J; Souček K; Hampl A; Beneš P
Sci Rep; 2022 Jun; 12(1):9583. PubMed ID: 35688908
[TBL] [Abstract][Full Text] [Related]
2. DNA demethylation and tri-methylation of H3K4 at the TACSTD2 promoter are complementary players for TROP2 regulation in colorectal cancer cells.
Gehring A; Huebner K; Rani H; Erlenbach-Wuensch K; Merkel S; Mahadevan V; Grutzmann R; Hartmann A; Schneider-Stock R
Sci Rep; 2024 Feb; 14(1):2683. PubMed ID: 38302503
[TBL] [Abstract][Full Text] [Related]
3. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
Vidula N; Yau C; Rugo H
Breast Cancer Res Treat; 2022 Aug; 194(3):569-575. PubMed ID: 35789445
[TBL] [Abstract][Full Text] [Related]
4. Identification of TROP2 (TACSTD2), an EpCAM-like molecule, as a specific marker for TGF-β1-dependent human epidermal Langerhans cells.
Eisenwort G; Jurkin J; Yasmin N; Bauer T; Gesslbauer B; Strobl H
J Invest Dermatol; 2011 Oct; 131(10):2049-57. PubMed ID: 21677668
[TBL] [Abstract][Full Text] [Related]
5. Trop2 marks transient gastric fetal epithelium and adult regenerating cells after epithelial damage.
Fernandez Vallone V; Leprovots M; Strollo S; Vasile G; Lefort A; Libert F; Vassart G; Garcia MI
Development; 2016 May; 143(9):1452-63. PubMed ID: 26989172
[TBL] [Abstract][Full Text] [Related]
6. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes.
Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Subat S; Nagano H; Nomura K; Okumura S; Shibutani T; Ishikawa Y
Oncotarget; 2017 Apr; 8(17):28725-28735. PubMed ID: 28404926
[TBL] [Abstract][Full Text] [Related]
7. Single-sEV profiling identifies the TACSTD2 + sEV subpopulation as a factor of tumor susceptibility in the elderly.
Ning N; Lu J; Li Q; Li M; Cai Y; Wang H; Li J
J Nanobiotechnology; 2024 May; 22(1):222. PubMed ID: 38698420
[TBL] [Abstract][Full Text] [Related]
8. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway.
Nakanishi H; Taccioli C; Palatini J; Fernandez-Cymering C; Cui R; Kim T; Volinia S; Croce CM
Oncogene; 2014 Feb; 33(6):702-12. PubMed ID: 23416980
[TBL] [Abstract][Full Text] [Related]
9. Ginsenoside Rb3 Alleviates CSE-induced TROP2 Upregulation through p38 MAPK and NF-κB Pathways in Basal Cells.
Li H; Cui L; Liu Q; Dou S; Wang W; Xie M; Xu X; Zheng C; Li T; Huang S; Cui X; Xiao W
Am J Respir Cell Mol Biol; 2021 Jun; 64(6):747-759. PubMed ID: 33705682
[TBL] [Abstract][Full Text] [Related]
10. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
11. Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis.
Wang F; Liu X; Yang P; Guo L; Liu C; Li H; Long S; Shen Y; Wan H
Cell Death Dis; 2014 Mar; 5(3):e1133. PubMed ID: 24651436
[TBL] [Abstract][Full Text] [Related]
12. Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma.
Sawanyawisuth K; Tantapotinan N; Wongkham C; Riggins GJ; Kraiklang R; Wongkham S; Puapairoj A
Ann Hepatol; 2016; 15(1):71-81. PubMed ID: 26626643
[TBL] [Abstract][Full Text] [Related]
13. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics.
Goldstein AS; Lawson DA; Cheng D; Sun W; Garraway IP; Witte ON
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20882-7. PubMed ID: 19088204
[TBL] [Abstract][Full Text] [Related]
14. Variation of Trop2 on non-small-cell lung cancer and normal cell membranes revealed by super-resolution fluorescence imaging.
Fu Y; Jing Y; Gao J; Li Z; Wang H; Cai M; Tong T
Talanta; 2020 Jan; 207():120312. PubMed ID: 31594569
[TBL] [Abstract][Full Text] [Related]
15. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.
Ahmed Y; Berenguer-Pina JJ; Mahgoub T
Oncology; 2021; 99(10):673-680. PubMed ID: 34280931
[TBL] [Abstract][Full Text] [Related]
16. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling.
Stoyanova T; Goldstein AS; Cai H; Drake JM; Huang J; Witte ON
Genes Dev; 2012 Oct; 26(20):2271-85. PubMed ID: 23070813
[TBL] [Abstract][Full Text] [Related]
17. TROP2 methylation and expression in tamoxifen-resistant breast cancer.
Zimmers SM; Browne EP; Williams KE; Jawale RM; Otis CN; Schneider SS; Arcaro KF
Cancer Cell Int; 2018; 18():94. PubMed ID: 30002602
[TBL] [Abstract][Full Text] [Related]
18. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.
Liu X; Deng J; Yuan Y; Chen W; Sun W; Wang Y; Huang H; Liang B; Ming T; Wen J; Huang B; Xing D
Pharmacol Ther; 2022 Nov; 239():108296. PubMed ID: 36208791
[TBL] [Abstract][Full Text] [Related]
19. v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.
Ju X; Jiao X; Ertel A; Casimiro MC; Di Sante G; Deng S; Li Z; Di Rocco A; Zhan T; Hawkins A; Stoyanova T; Andò S; Fatatis A; Lisanti MP; Gomella LG; Languino LR; Pestell RG
Cancer Res; 2016 Nov; 76(22):6723-6734. PubMed ID: 27634768
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated calcium signal transducer 2 regulates neovascularization of non-small-cell lung cancer via activating ERK1/2 signaling pathway.
Guo X; Zhu X; Zhao L; Li X; Cheng D; Feng K
Tumour Biol; 2017 Mar; 39(3):1010428317694324. PubMed ID: 28345466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
